von Kempis, Johannes; Dudler, Jean; Hasler, Paul; Kyburz, Diego; Tyndall, Alan; Zufferey, Pascal; Villiger, Peter M (2012). Use of abatacept in rheumatoid arthritis. Swiss medical weekly, 142, w13581. Muttenz: EMH Schweizerischer Ärzteverlag 10.4414/smw.2012.13581
Full text not available from this repository. (Request a copy)Abatacept (CTLA-Ig), a modulator of T-lymphocyte activation, has been approved by the Swiss health regulatory agency Swissmedic for the treatment of active rheumatoid arthritis (RA). This article summarises the key trial findings for this biologic agent in RA in different situations such as early erosive rheumatoid arthritis (RA), biologic-naïve RA, RA before and after the use of methotrexate or TNF-inhibitors and includes safety information from these trials. Based on these data, recommendations for clinical practice in Switzerland are made by a panel of experts.
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology |
UniBE Contributor: |
Villiger, Peter Matthias |
ISSN: |
1424-7860 |
Publisher: |
EMH Schweizerischer Ärzteverlag |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:40 |
Last Modified: |
05 Dec 2022 14:12 |
Publisher DOI: |
10.4414/smw.2012.13581 |
PubMed ID: |
22581564 |
Web of Science ID: |
000303936900001 |
URI: |
https://boris.unibe.ch/id/eprint/16315 (FactScience: 223926) |
Actions (login required)
 |
Edit item |